Net debt swung to $20.1m as cash conversion collapsed to 19.8%

Operating cash flow fell 70.5% to $6.0m while EBITDA was essentially flat at $30.2m, so OCF/EBITDA conversion dropped from 66.6% to 19.8%. Capex rose 83.9% to $10.3m (3.7% of revenue versus 2.1%), turning free cash flow from +$14.7m to roughly –$4.4m and FCF/NPAT from 95% to –55.6%. Net debt swung from $0.1m to $20.1m as gross borrowings climbed 47.5% to $31.7m and cash fell 45.5% to $11.7m.

Headline revenue grew 3.2% to $276.1m on what management calls a record FY23, but the operating mix shifted: Materials Handling revenue rose to $127.3m (46.1% share, up from 35.3%), Protein fell about 21% to $59.9m with segment gross margin down from 33% to 28%, and Minerals margin slipped from 40% to 36%. PBT fell 42.7% and NPAT fell 48.7%, the latter widened by an effective tax rate of 29.6% versus 19.6%.

• OCF/EBITDA at 19.8% versus 66.6% prior is the headline. The largest balance-sheet driver is contract liabilities falling 34.5% (–$15.7m), which means delivered work was recognised without a matching replenishment of customer pre-billings. Combined with the capex step-up, this turned FCF negative and absorbed essentially all of the prior cash buffer, leaving net debt/EBITDA at 0.66x from a near-zero base. For a project-based industrial this is execution risk: working-capital release was supporting the prior cash result.

• Earnings shape below EBITDA. EBITDA was flat, but depreciation/amortisation, interest on a larger borrowings stack, and a 1,000bps higher effective tax rate compressed PBT by 42.7% and NPAT by 48.7%. The 6.0 percentage-point PBT-to-NPAT growth gap is tax driven, with no explanation visible in the supplied excerpts. The cleaner operating read is PBT, which is down 42.7% – materially worse than the EBITDA line implies.

• Segment mix conceals margin pressure. Materials Handling carried the revenue line, but Protein revenue dropped about 21% and its gross margin fell roughly 500bps; Minerals margin fell 400bps. Group EBITDA flatness is partly a mix outcome, not consistent core profitability across sectors.

The HY24 shape was first-half-weighted (H1 was 56.5% of full-year NPAT), so the H2 NPAT run-rate of roughly $3.4m is the more relevant base for FY25 modelling.

Against the stated Destination 2030 target of $530m revenue by FY30, the implied CAGR from the FY24 base is 11.5%, well ahead of the 3.2% delivered this year. The release does not provide bridging targets, segment growth aspirations, or capex plans to support that trajectory, so investors are being asked to take the multi-year shape on trust.

Operating cash conversion at 19.8% is the cleanest signal that this year's earnings were not turned into cash at anything like the prior rate, and the $7.2m increase in operating working capital plus the $15.7m fall in contract liabilities indicate the cash gap is structural to this year's project cycle rather than a single timing item. Receivable days (53.2) and inventory days (48.8) both improved, so the strain is concentrated on the customer-prepayment side, not collections.

Capital allocation is now stretched against this cash profile. Full-year dividends per share are 8.0 cents – the same total as FY23 – but the payout ratio against NPAT has risen from 20.7% to 82.5%, and FCF is negative, so the distribution was effectively balance-sheet-funded. ROE fell from 13.5% to 7.0%. If cash conversion does not normalise in FY25, the combination of higher capex, the dividend, and a near-tripled borrowings position will continue to lift leverage from here.

This briefing cannot assess management's internal forecast for FY25 cash conversion, the maturity profile of the increased borrowings, or whether contracted backlog supports a return to the prior cash-generation pattern.